Clinical Trial Detail

NCT ID NCT02879318
Title Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

pancreatic ductal adenocarcinoma

Therapies

Gemcitabine + Nab-paclitaxel

Durvalumab + Tremelimumab

Age Groups: adult senior

No variant requirements are available.